Scientific Program Day One | Wednesday, February 22, 2023

8:20 am Chairperson’s Opening Remarks

Showcasing Next-Generation Conjugates Paving a Way for the Novel Modality

8:30 am Design & Optimization of SMDCs Targeting the Tumor Microenvironment


  • Discussing tailored SMDC design: More than just connecting a payload to a homing device
  • Understanding optimal linker strategies, a thin line between stability and targeted payload release and delivery
  • Providing a case study of VIP236, a first-in-class SMDC

9:00 am DYNE-101 & DYNE-251: Moving From Bench to Clinic to Deliver Potentially Transformative Therapies in DM1 & DMD


  • Sharing how the FORCETM platform harnesses the natural expression of transferrin receptor 1 (TfR1) on muscle cells for targeted delivery of rationally selected payload with the goal of addressing the underlying causes of rare and genetic muscle diseases
  • Discussing robust data using multiple preclinical models to validate the two lead FORCE conjugates, DYNE-101 and DYNE-251
  • DYNE-101 and DYNE-251 are currently being studied in Phase I/II clinical trials for the treatment of DM1 and DMD

9:30 am The Development of Bicycles as Precision Guided Therape

  • Gavin Bennett Senior Director, Program Team Leader, Bicycle Therapeutics


  • Bicycles offer the affinity and selectivity of antibodies in a small molecule format
  • Understand how Bicycles targeting the tumor antigens can provide rapid delivery of payloads to tumor cells, whilst limiting exposure to normal tissues
  • Learn about the Bicycle Toxin Conjugates (BTCs) and Tumor-targeted Immune Cell
  • Activators (TICA) that are being developed to offer novel therapeutic options to patients

10:00 am Speed Networking


This session is an opportunity to connect with peers working within the Next- Generation Conjugate world to have important conversations to overcome shared challenges, and plot paths to see future successes within the field.

11:00 am Leveraging Novel Expression Platforms & Precise Conjugation to Enable Immunostimulatory Antibody-Drug Conjugates (iADCs)

  • Gang Yin Executive Director, Sutro Biopharma


  • Providing an overview of Sutro’s proprietary cell-free expression system and site-specific conjugation technology
  • Outlining the combination of an in vitro and in vivo platform to enable precise dual conjugation
  • Assessing how combining ADC and immune agonists can potentially break tumor tolerance and elicit protective immunity in a single therapy

11:30 am Targeting STING to CCR2+ Cells Via an Immune Stimulating Antibody Conjugate

  • Vicky Appleman STING Discovery Lead (Principal Scientist), Takeda Pharmaceutical Co. Ltd.


  • The murine surrogate ISAC, mTAK-500, was designed to selectively deliver the STING agonist, TAK-676, to CCR2+ cells mTAK-500 enabled the characterization of the exposure, potency, mechanism, and anti-tumor activity of targeting STING to CCR2+ cells
  • CCR2-mediated delivery of TAK-676 triggered dose-dependent activation of the STING signaling pathway, as well as robust activation of innate and adaptive immune activity both in vitro and in vivo. This activation led to durable anti-tumor responses in preclinical models
  • Nonclinical anti-tumor activity and mechanistic insight have motivated design and clinical testing of TAK-500, a CCR2-targeted STING ISAC comprising the clinical STING agonist TAK-676 and a high affinity antibody targeting human CCR2, as a single agent and in combination with pembrolizumab in adults with select locally advanced or metastatic solid tumors

12:00 pm A Novel Antibody Drug Affinity Conjugate (ADAC) Based on a Multispecific Anti-CD40 Antibody Improves Modular Peptide Delivery & Efficient T Cell Activation

  • Ida Lauren PhD Student & Co-Founder, Strike Pharma


  • Overviewing the ADAC technology as an adaptable platform to tackle the challenges and needs of patient-specific peptide vaccines in cancer
  • Reviewing the challenges and learnings when developing a multispecific antibody with agnostic properties, being the key molecule in the ADAC technology
  • Evaluating the in vitro and in vivo efficacy of targeted peptide delivery to dendritic cells via the CD40 pathway

12:30 pm Lunch

Showcasing Groundbreaking Approaches Harnessing Novel Targeting Formats

1:30 pm Moving From Bench to Bedside: Transitioning the Novel PDC TH1902 From the Preclinical to the Clinical Setting


  • Sortilin is a novel receptor overexpressed in cancer, whose normal function as a scavenger receptor can be exploited to rapidly transport cytotoxic drugs into cancer cells
  • Learn about the validation of the unique MoA and kinetics of internalization of TH1902 into the cancer cells
  • Gain insight into the status of the Phase I Study (Part I Dose Escalation, Part II basket trial in multiple tumor types) including study design, dosing, safety and early signs of efficacy

2:00 pm Developing Antibody Fragment Drug Conjugates for Solid Tumors


  • Fine-tuning our FDC discovery platform to discover antibody fragments and linker-payloads tailored for solid tumors
  • Outlining the discovery of Antikor’s lead FDC program (ANT-045) and follow-up programs
  • Reviewing the development of ANT-045 FDC in advanced models for tumor cure efficacy and safety

2:30 pm Afternoon Break & Refreshments

Sharing Developments Made Within the Oligonucleotide Field

3:00 pm Engineering Antibody Oligonucleotide Conjugates (AOCs): Taking Receptor-Mediated Delivery One Step Further


  • Discussing antibody-oligonucleotide conjugates
  • Exploring how antibody-oligonucleotides can help solve oligo delivery challenges
  • Delving into the efficacy of multiple AOCs in preclinical models

3:30 pm Oligonucleotide Therapies: A Twist on Oligoconjugates


  • Overviewing the challenges and opportunities in oligoconjugates
  • Discussing phospholipid ether platform as an ideal delivery mechanism
  • Outlining future directions

4:00 pm Development of Antibody Oligonucleotide Conjugates as Tissue-Targeted RNA Therapies

  • Fu-An Kang Vice President, Research, MiRecule Inc.


  • Adressing the challenges and potetials of RNA therapies
  • Discussing the development of oligonucleotides and their antibody conjugates as tissue-targeted RNA therapies
  • Introducing the BioCoat technology to improve the delivery of RNA therapies

4:30 pm End of Conference Day One

4:45 pm Scientific Poster Session


With the formal presentations over for the day the sharing and learning doesn’t stop as the Scientific Poster Session takes place. This will serve as the perfect opportunity to share your recent work with the community.